Business Context and Reporting Period
Pulmatrix, Inc. filed this Form 8-K on September 5, 2017, reporting the entry into a Material Definitive Agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a potential future revenue stream based on a licensing agreement:
- Upfront Payment: A one-time technology access fee of $1,000,000 is payable by Vectura Limited within 45 days of successfully completing a Feasibility Study.
- Royalties: A mid-teen percentage of payments received by Vectura from commercial sales of licensed products in the United States.
Material Changes
The primary material change is the execution of a Feasibility and Development Agreement with Vectura Limited. Key terms include:
- Grant of an exclusive, sub-licensable, royalty-bearing license for Pulmatrix's iSPERSE technology and specific formulations (tiotropium and olodaterol) for the U.S. market.
- Transfer of responsibility for all future development costs and discretion to Vectura.
- Requirement for Vectura to conduct a Feasibility Study using a pre-agreed pharmaceutical development plan.
Outlook, Risks, and Contingencies
Outlook: Future revenue is contingent upon the successful completion of the Feasibility Study and subsequent commercial sales. The agreement remains in effect until the last sale of the last licensed product.
Risks and Termination:
- Vectura may terminate the agreement for any reason upon three months' notice.
- Either party may terminate upon insolvency or material breach of the other party.
- The $1,000,000 fee is not guaranteed and depends on the successful completion of the Feasibility Study.
Investor Verification Checklist
- Verify the status and timeline of the Feasibility Study to assess the likelihood of receiving the $1,000,000 access fee.
- Review the specific "mid-teen percentage" royalty rate defined in the full agreement text.
- Monitor Vectura's progress in developing the inhaler device and formulation.
- Assess the risk of early termination by Vectura under the three-month notice clause.